Navigation Links
PARP inhibitor shows activity in pancreatic, prostate cancers among patients carrying BRCA mutations
Date:5/15/2013

PHILADELPHIA In the largest clinical trial to date to examine the efficacy of PARP inhibitor therapy in BRCA 1/2 carriers with diseases other than breast and ovarian cancer, the oral drug olaparib was found to be effective against advanced pancreatic and prostate cancers. Results of the study, led by researchers from the Perelman School of Medicine at the University of Pennsylvania and Sheba Medical Center in Tel Hashomer, Israel, will be presented during the American Society of Clinical Oncology's annual meeting in Chicago in early June (Abstract #11024).

The multi-center research team, including investigators from across the United States, Europe, Australia and Israel, studied nearly 300 patients with inherited BRCA1 and BRCA2 mutations who had advanced cancers that were still growing despite standard treatments. Study participants, comprised of patients with breast, ovarian, pancreatic, prostate and other cancers, all took olaparib.

"Our results show that the BRCA1 or BRCA2 genes inherited by some patients can actually be the Achilles heel in a novel, personalized approach to treat any type of cancer the patient has," says the study's senior author, Susan Domchek, MD, director of Penn's Basser Research Center for BRCA, the nation's only center devoted solely to research for prevention and treatment associated with BRCA mutations. "As many as 3 percent of patients with pancreatic and prostate cancer have an inherited mutation in BRCA1 or BRCA2. Our findings have implications for many patients beyond those with breast and ovarian cancer."

Five of 23 pancreatic cancer patients (22 percent) and four of eight prostate cancer patients (50 percent) responded to the therapy, as measured by objective clinical criteria. Importantly, the therapy also appeared to halt disease progression even in those whose tumors did not shrink: an additional eight (35 percent) of the pancreatic cancer patients studied had stable disease at 8 weeks after b
'/>"/>

Contact: Holly Auer
holly.auer@uphs.upenn.edu
215-200-2313
University of Pennsylvania School of Medicine
Source:Eurekalert

Page: 1 2

Related biology news :

1. Blocking DNA: HDAC inhibitor targets triple negative breast cancer
2. Study identifies pathway to enhance usefulness of EGFR inhibitors in lung cancer treatment
3. New inhibitors of elusive enzymes promise to be valuable scientific tools
4. Team solves birth and migration mysteries of cortexs powerful inhibitors, chandelier cells
5. MDC and FMP researchers identify edema inhibitor
6. Genetic survey of endangered Antarctic blue whales shows surprising diversity
7. University of Houston study shows BP oil spill hurt marshes, but recovery possible
8. Weakness can be an advantage in surviving deadly parasites, a new study shows
9. Study shows unified process of evolution in bacteria and sexual eukaryotes
10. Sexual reproduction brings long-term benefits, study shows
11. UCSB study shows forest insects and diseases arrive in US via imported plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/4/2014)... amount of death at the right time might actually ... research that could help in understanding animal populations, pest ... a paper in the journal Trends in Ecology ... colleagues conclude that the kind of positive population effect ... or mortality, depends on the size and developmental stage ...
(Date:11/4/2014)...   3D scanner ... Fuel3D , a developer of 3D scanning solutions, ... $6.4 million (£4 million). This funding builds on the company,s ... and paves the way for the commercial launch of the ... round was led by Chimera Partners and will be used ...
(Date:11/3/2014)... of Colorado Cancer Center study published in ... Sciences describes the activity of a recently discovered ... or IL-37. It has been known to limit inflammation ... adaptive immune system: IL-37 inhibits the ability of the ... "Knowing this mechanism that underlies IL-37,s effect on the ...
Breaking Biology News(10 mins):When less is more: Death in moderation boosts population density in nature 2Fuel3D Secures $6.4 Million in Expansion Funding 2Fuel3D Secures $6.4 Million in Expansion Funding 3PNAS: From HIV to cancer, IL-37 regulates immune system 2
... a link between massive volcanic eruptions along the east coast ... million years ago and a period of global warming that ... tropics and more than six degrees in the Arctic. , ... , The study is important, experts say, because it ...
... 243 acres in an East Tennessee valley adjacent to ... toxic waste from weapons manufacturing at the facility between ... radioactive plumes for miles from the contaminated site. ... Kostka and his FSU oceanography department team will help ...
... a decade’s worth of statistics, researchers are sounding a new ... men. , The overall number of syphilis cases in the ... in 2003 perhaps because of a nationwide prevention campaign aimed ... significantly in this decade. , "The entire nation ...
Cached Biology News:Volcanic eruptions, ancient global warming linked 2Volcanic eruptions, ancient global warming linked 3'Hidden-hero' microbes in soil, water may help naturally clean toxic sites 2Syphilis rate on rise in US gay, bisexual men 2
(Date:11/27/2014)... USA (PRWEB) November 26, 2014 Biomedical ... accuracy, additive systems to enable 3D manufacture at the ... road conditions are among finalists in nine categories for ... The awards are sponsored by SPIE, the international ... Media . , Winners will be announced by industry ...
(Date:11/26/2014)... (PRWEB) November 26, 2014 2014 ... is a professional and in-depth research report on ... information, like its definition, classification, application, and industry ... report covers the international market analysis, including China’s ... the US, Europe, Asia, China, Japan etc. regions) ...
(Date:11/26/2014)... YORK , Nov. 26, 2014 The ... may indicate the company is looking to expand in ... further sales.  The healthcare market research firm says that  ... to Kalorama Information,s biennial survey of the IVD market ... and any change in its composition would likely affect ...
(Date:11/26/2014)... November 26, 2014 On January, 14, ... Baltimore and Washington D.C. science community to the UMBC ... event, sponsored by the Protein Society, will take place ... Center, Room 312. Through discussion, presentations and workshops, ... importance of proteins, their role in the industry and ...
Breaking Biology Technology:Finalists Named for 2015 Prism Awards for Photonics Innovation 2Finalists Named for 2015 Prism Awards for Photonics Innovation 3Finalists Named for 2015 Prism Awards for Photonics Innovation 4Finalists Named for 2015 Prism Awards for Photonics Innovation 5Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 2Ammonium Bifluoride Market International Analysis of Manufacturing, Technology & Trends Now at ReportsnReports.com 3Kalorama: Sale of Three Siemens Healthcare Units Raises Questions About Firm's IVD Future 2
... Continuous Enhancement Model and Customer Advisory Board Programs ... Service Leader in Talent Management Market, OTTAWA, ... leading,provider of web-based employee performance and talent management ... valuable insight,into real-life HR issues and challenges and ...
... Three Hospitals in Western Pennsylvania Earn Designation, ... Shield,has named Allegheny General Hospital, UPMC Presbyterian Shadyside ... and Rare Cancers., Complex and rare cancers ... year, making it difficult for patients to locate ...
... March 11 Cardium Therapeutics,(Amex: CXM ) ... by researchers at Emory University, which demonstrated highly,efficient ... muscle lacking sufficient blood flow as a result ... an occlusion and reperfusion model,analogous to a heart ...
Cached Biology Technology:Halogen Customers Shape Industry-Leading Employee Performance and Talent Management Solution 2Halogen Customers Shape Industry-Leading Employee Performance and Talent Management Solution 3Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 2Highmark Blue Cross Blue Shield and National Association Name Area Hospitals as Blue Distinction Centers for Complex and Rare Cancers 3Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 2Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 3Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 4Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 5Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 6Cardium's Corgentin Preclinical Program Shows High Levels of Targeting to Acutely Ischemic Heart Muscle Following Intracoronary Infusion 7
... Blasticidin is a nucleoside ... It is a potent ... prokaryotic and eukaryotic cells. ... conferred by the products ...
... Polyclonal Antibody against Aph-1a (Aph-1aL,S Loop ... gamma secretase is a multiprotein complex ... Pen-2; all four proteins are necessary ... secretase complex catalyzes cleavage of a ...
... are a group of enzymes important in ... mammals. The enzymes protect cells against toxicants ... glutathione to electrophilic xenobiotics, and thereby defend ... effects of the compounds. GST activity is ...
15(S)-HEDE is produced from 11Z,14Z-eicosadienoic acid by 15-LO. 15(S)-HEDE is an inhibitor of RBL-1 cell 5-LO with an IC50 value of 26 µM....
Biology Products: